Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| VRX | Valeant Pharmaceuticals International, Inc. | 0.28% | 14.38 | 14.2% | $232.56m | |
| SHPG | Shire PLC Sponsored ADR | -1.62% | 145.55 | 0.4% | $212.81m | |
| PRGO | Perrigo Co. Plc | -0.49% | 77.31 | 6.4% | $151.41m | |
| MNK | Mallinckrodt Plc | 0.11% | 36.40 | 17.7% | $118.87m | |
| UTHR | United Therapeutics Corporation | -1.50% | 129.10 | 13.9% | $86.64m | |
| JAZZ | Jazz Pharmaceuticals Plc | -1.10% | 144.40 | 2.2% | $77.81m | |
| ENDP | Endo International Plc | 1.04% | 8.72 | 8.9% | $71.06m | |
| ALR | Alere Inc. | 0.43% | 49.54 | 2.7% | $68.28m | |
| HZNP | Horizon Pharma plc | 1.29% | 13.31 | 7.6% | $66.17m | |
| PRXL | PAREXEL International Corporation | 0.02% | 87.66 | 7.9% | $66.07m | |
| ICPT | Intercept Pharmaceuticals, Inc. | -0.11% | 104.08 | 22.1% | $61.01m | |
| NDRM | NeuroDerm Ltd. | 0.00% | 38.55 | 3.6% | $48.20m | |
| MYOK | MyoKardia, Inc. | -7.18% | 40.38 | 3.0% | $47.43m | |
| PTLA | Portola Pharmaceuticals, Inc. | 1.45% | 53.99 | 8.9% | $43.40m | |
| MDCO | Medicines Company | 0.28% | 35.50 | 22.3% | $41.20m |
Company Profile
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.